|
Aug 28
|
Neurocrine Biosciences to Participate at Investor Conferences in September
|
|
Aug 28
|
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
|
|
Aug 28
|
Neurocrine’s mixed schizophrenia data disappoint Wall Street
|
|
Aug 28
|
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
|
|
Aug 8
|
Statutory Profit Doesn't Reflect How Good Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are
|
|
Aug 7
|
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
|
|
Aug 6
|
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
|
|
Jul 10
|
Top Medical Stocks to Buy for Growth & Performance
|
|
Jun 14
|
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
|
|
Jun 12
|
Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%
|
|
May 29
|
Neurocrine Biosciences to Participate at Investor Conferences in June
|
|
May 28
|
Neurocrine Biosciences Announces CEO Succession Plan
|
|
May 28
|
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
|
|
May 14
|
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
|
|
May 9
|
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
|
|
May 9
|
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
|
|
May 9
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
|
|
May 8
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
|
|
May 7
|
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
|
|
May 7
|
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
|